View More View Less
  • 1 Çankiri Karatekin University, Turkey
  • 2 Manisa Celal Bayar University, Turkey
  • 3 Ondokuz Mayis University, Turkey
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

Immunogenic potency of the recombinant Erp, HspR, LppX, MmaA4, and OmpA proteins from Mycobacterium tuberculosis (MTB), formulated with Montanide ISA 720 VG adjuvant, was evaluated in BALB/c mice for the first time in this study. The five vaccine formulations, adjuvant, and BCG vaccine were subcutaneously injected into mice, and the sera were collected at days 0, 15, 30, 41, and 66. The humoral and cellular immune responses against vaccine formulations were determined by measuring serum IgG and serum interferon-gamma (IFN-γ) and interleukin-12 (IL-12) levels, respectively. All formulations significantly increased IgG levels post-vaccination. The highest increase in IFN-γ level was provided by MmaA4 formulation. The Erp, HspR, and LppX formulations were as effective as BCG in enhancement of IFN-γ level. The most efficient vaccine boosting the IL-12 level was HspR formulation, especially at day 66. Erp formulation also increased the IL-12 level more than BCG at days 15 and 30. The IL-12 level boosted by MmaA4 formulation was found to be similar to that by BCG. OmpA formulation was inefficient in enhancement of cellular immune responses. This study showed that MmaA4, HspR, and Erp proteins from MTB are successful in eliciting both humoral and cellular immune responses in mice.

Supplementary Materials

    • Supplementary Material

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jun 2020 0 4 1
Jul 2020 21 4 4
Aug 2020 22 0 0
Sep 2020 18 2 0
Oct 2020 34 1 1
Nov 2020 9 2 1
Dec 2020 0 0 0